This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Trevena (TRVN) Initiates Proof-of-Concept for Epilepsy Candidate
by Zacks Equity Research
Trevena (TRVN) has initiated proof-of-concept study to evaluate TRV045 as a potential treatment for epilepsy and other CNS disorders.
TRVNPositive Net Change CRSPNegative Net Change KALAPositive Net Change ALLONegative Net Change
biotechnology medical
ViaSat (VSAT) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
VSATNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Protagonist (PTGX) Up on Positive Results From FRONTIER Study
by Zacks Equity Research
Protagonist (PTGX) gains as the phase II study, conducted by Janssen, achieves its primary goal.
JNJPositive Net Change GERNNegative Net Change AMRNNegative Net Change PTGXPositive Net Change
biotechnology biotechs pharmaceuticals
After Golden Cross, Payoneer Global Inc. (PAYO)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PAYOPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Bank of NT Butterfield & Son (NTB) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
NTBPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Duolingo, Inc. (DUOL)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
DUOLNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Sanofi (SNY), Regeneron Dupixent sBLA Accepted for FDA Review
by Zacks Equity Research
Sanofi's (SNY) sBLA seeking label expansion of drug Dupixent for chronic spontaneous urticaria accepted by the FDA
REGNNegative Net Change SNYNegative Net Change CRSPNegative Net Change ALLONegative Net Change
biotechnology medical oncology-screening
Carrols Restaurant Group (TAST) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
TASTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Navitas Semiconductor Corporation (NVTS) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
NVTSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Incyte (INCY) Discontinues Jakafi Combo Myelofibrosis Study
by Zacks Equity Research
Incyte (INCY) decides to scrap the LIMBER-304 study evaluating the efficacy and safety of parsaclisib plus Jakafi for myelofibrosis (MF) following an independent data monitoring committee recommendation.
NVSNegative Net Change LLYNegative Net Change INCYPositive Net Change
biotechnology biotechs
Exelixis' (EXEL) Cabozantinib Combo Study Fails to Meet Goal
by Zacks Equity Research
Exelixis' (EXEL) combo-drug study for kidney cancer fails to meet the primary endpoint of progression-free survival (PFS).
RHHBYNegative Net Change BMYPositive Net Change EXELNegative Net Change
biotechnology biotechs
KALA Q4 Loss Wider Than Expected, Pipeline Remains in Focus
by Zacks Equity Research
Kala's Q4 earnings miss estimates. Its shares rise in pre-market trading on Mar 6.
CRSPNegative Net Change KALAPositive Net Change RCUSNegative Net Change ALLONegative Net Change
biotechnology earnings medical
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top
by Zacks Equity Research
Puma Biotechnology's (PBYI) Q4 2022 loss is wider than estimates, Revenues beat the same.
PBYINegative Net Change CRSPNegative Net Change RCUSNegative Net Change ALLONegative Net Change
biotechnology earnings medical
Intercept (ICPT) Q4 Earnings Beat, Ocaliva Sales Increase
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss in Q4 due to higher revenues.
GERNNegative Net Change AMRNNegative Net Change ICPTPositive Net Change VKTXNegative Net Change
biotechnology biotechs earnings pharmaceuticals
Amarin's (AMRN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amarin Corporation's (AMRN) fourth-quarter 2022 earnings and revenues beat estimates; Vascepa sales decline.
AMRNNegative Net Change CRSPNegative Net Change RCUSNegative Net Change ALLONegative Net Change
biotechnology earnings medical
Amicus (FOLD) Q4 Earnings Miss, Galafold Sales Beat Estimates
by Zacks Equity Research
Amicus (FOLD) posts a wider-than-expected fourth-quarter loss but strong sales of its solely marketed drug Galafold drive the top line.
GERNNegative Net Change FOLDPositive Net Change AMRNNegative Net Change
biotechnology biotechs pharmaceuticals
Biotech Stock Roundup: MRNA Q4 Earnings, REGN's Updates, CYTK Receives Setback
by Zacks Equity Research
Earnings from Moderna (BIIB) and updates from Regeneron (REGN) are the key highlights from the biotech sector during the past week.
REGNNegative Net Change INCYPositive Net Change MRNANegative Net Change CYTKNegative Net Change
biotechnology biotechs
FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
FATE reports a narrower loss and higher collaboration revenues for the fourth quarter.
JNJPositive Net Change GERNNegative Net Change AMRNNegative Net Change FATENegative Net Change
biotechnology biotechs pharmaceuticals
Main Street Capital (MAIN)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
MAINPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Axsome (AXSM) Q4 Earnings Miss, Auvelity Records First Sales
by Zacks Equity Research
Axsome Therapeutics (AXSM) incurs wider-than-expected loss in Q4 2022. Revenues beat estimates while shares gain.
JAZZPositive Net Change AXSMNegative Net Change BGNEPositive Net Change CRSPNegative Net Change
biotechnology earnings medical
Theravance's (TBPH) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Thervance's (TBPH) fourth-quarter loss wider than expected. Revenues decline year over year.
JNJPositive Net Change TBPHNegative Net Change CRSPNegative Net Change VTRSPositive Net Change
biotechnology earnings medical
ePlus (PLUS)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PLUSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Immunocore (IMCR) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Immunocore's (IMCR) Q4 earnings call, investors will likely focus on the sales figure of Kimmtrak - its first-line treatment for metastatic uveal melanoma - and updates on its pipeline candidates.
ICPTPositive Net Change SNDXNegative Net Change BGNEPositive Net Change IMCRNegative Net Change
biotechnology medical oncology-screening
Durables Goods Sink -4.5%, but Higher on Business Spending
by Mark Vickery
These Durable Goods figures are preliminary, and subject to future revisions.
PFEPositive Net Change QQQNegative Net Change SPYNegative Net Change SGENPositive Net Change DIANegative Net Change
biotechnology medical pharmaceuticals
Amerant Bancorp Inc. (AMTB) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
AMTBPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines